Research reveals new therapeutic target for Huntington's disease

January 8, 2014

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted. The research is published online in Human Molecular Genetics.

HD is an inherited neurodegenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.

Working in the Ferguson lab where Ribeiro was a postdoctoral trainee, the scientists crossed two mouse models. One was a mouse which doesn't have glutamate receptors –they've been knocked out genetically, and the other is a HD which over-expresses mutant human Huntington protein. They found if they deleted mGluR5, they lost the pathology of Huntington's in the neurons, and they saw improvements in motor behavior which normally would be impaired in these mice.

This video is not supported by your browser at this time.
Stephen Ferguson, Ph.D., a scientist at Western University's Robarts Research Institute found a definite improvement in motor behaviours in a Huntington's disease mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 was deleted. Credit: Western University

"What we found was, if we block mGluR5, which is the we're interested in, the mice become hyper locomotive so they become able to move better than wild type mice suggesting glutamate receptors might be a good target for treating movement disorders such as Parkinson's disease. So that was a bit of a surprise that came out in the study, and we can show that genetically and pharmaceutically," says Ferguson who holds a Canada Research Chair in Molecular Neurobiology. "And the good thing is, there are mGluR5 antagonists now in stage three clinical trials for diseases such as Fragile X, so it is quite possible these drugs will be available for patients in the future."

Related Stories

Research targets brain region affected by Parkinson's

November 8, 2011

A team of researchers at The University of Western Ontario has demonstrated that elimination of one of the neurotransmitters in the part of the brain associated with Parkinson's disease may improve brain function without ...

Alzheimer's missing link found

September 4, 2013

Yale School of Medicine researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer's disease, they report in the Sept. 4 issue of the journal Neuron. Researchers ...

Recommended for you

Improved memory thanks to irregular sleep-wake patterns

July 31, 2015

If you've had a good night's sleep, you are mentally more alert and your memory works more reliably. During sleep, a part of our forebrain called the prefrontal cortex remains active. It ensures that memories and learned ...

Take a trip through the brain (w/ Video)

July 30, 2015

A new imaging tool developed by Boston scientists could do for the brain what the telescope did for space exploration. In the first demonstration of how the technology works, published July 30 in the journal Cell, the researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.